Kristoff A Olson1, Alexis L Beatty2, Bettina Heidecker1, Mathilda C Regan3, Edward N Brody4, Trudi Foreman4, Shintaro Kato5, Robert E Mehler4, Britta S Singer4, Kristian Hveem6, Havard Dalen7, David G Sterling4, Richard M Lawn4, Nelson B Schiller1, Stephen A Williams4, Mary A Whooley8, Peter Ganz9. 1. Department of Medicine, University of California, San Francisco, CA, USA. 2. Department of Medicine, University of California, San Francisco, CA, USA Cardiology Section, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA Department of Medicine, University of Washington, Seattle, WA, USA. 3. The Veterans Health Research Institute, San Francisco, CA, USA. 4. SomaLogic Inc., Boulder, CO, USA. 5. NEC Corporation of America, USA. 6. Lifandis AS, Norway HUNT Research Center, Department of Public Health, NTNU, Trondheim, Norway. 7. Department of Medicine, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway MI Lab and Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Norway. 8. Department of Medicine, University of California, San Francisco, CA, USA Veterans Affairs Medical Center, San Francisco, CA, USA Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. 9. Department of Medicine, University of California, San Francisco, CA, USA Division of Cardiology, San Francisco General Hospital, San Francisco, CA, USA peter.ganz@ucsf.edu.
Abstract
AIMS: Growth differentiation factor 11 and/or its homologue growth differentiation factor 8 (GDF11/8) reverses age-related cardiac hypertrophy and vascular ageing in mice. We investigated whether GDF11/8 associates with cardiovascular outcomes, left ventricular hypertrophy (LVH), or age in humans. METHODS AND RESULTS: We measured plasma GDF11/8 levels in 928 participants with stable ischaemic heart disease in the Heart and Soul study. We adjudicated heart failure hospitalization, stroke, myocardial infarction, death, and their composite endpoint. Left ventricular hypertrophy was evaluated by echocardiography. We used multivariable Cox proportional hazards models to compare rates of cardiovascular events and death across GDF11/8 quartiles and logistic regression models to evaluate the association between GDF11/8 and LVH. Four hundred and fifty participants (48.5%) experienced a cardiovascular event or death during 8.9 years of follow-up. The adjusted risk of the composite endpoint was lower in the highest compared with the lowest GDF11/8 quartile [hazard ratio (HR), 0.45; 95% confidence interval (CI), 0.33-0.60; P < 0.001]. We replicated this relationship of GDF11/8 to adverse events in 971 participants in the HUNT3 cohort (adjusted HR, 0.34; 95% CI, 0.23-0.51; P < 0.001). Left ventricular hypertrophy was present in 368 participants (39.7%) at baseline. Participants in the highest quartile of GDF11/8 were less likely to have LVH than those in the lowest quartile (adjusted OR, 0.55; 95% CI, 0.35-0.86; P = 0.009). GDF11/8 levels were lower in older individuals (P < 0.001). CONCLUSION: In patients with stable ischaemic heart disease, higher GDF11/8 levels are associated with lower risk of cardiovascular events and death. Our findings suggest that GDF11/8 has similar cardioprotective properties in humans to those demonstrated in mice. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Growth differentiation factor 11 and/or its homologue growth differentiation factor 8 (GDF11/8) reverses age-related cardiac hypertrophy and vascular ageing in mice. We investigated whether GDF11/8 associates with cardiovascular outcomes, left ventricular hypertrophy (LVH), or age in humans. METHODS AND RESULTS: We measured plasma GDF11/8 levels in 928 participants with stable ischaemic heart disease in the Heart and Soul study. We adjudicated heart failure hospitalization, stroke, myocardial infarction, death, and their composite endpoint. Left ventricular hypertrophy was evaluated by echocardiography. We used multivariable Cox proportional hazards models to compare rates of cardiovascular events and death across GDF11/8 quartiles and logistic regression models to evaluate the association between GDF11/8 and LVH. Four hundred and fifty participants (48.5%) experienced a cardiovascular event or death during 8.9 years of follow-up. The adjusted risk of the composite endpoint was lower in the highest compared with the lowest GDF11/8 quartile [hazard ratio (HR), 0.45; 95% confidence interval (CI), 0.33-0.60; P < 0.001]. We replicated this relationship of GDF11/8 to adverse events in 971 participants in the HUNT3 cohort (adjusted HR, 0.34; 95% CI, 0.23-0.51; P < 0.001). Left ventricular hypertrophy was present in 368 participants (39.7%) at baseline. Participants in the highest quartile of GDF11/8 were less likely to have LVH than those in the lowest quartile (adjusted OR, 0.55; 95% CI, 0.35-0.86; P = 0.009). GDF11/8 levels were lower in older individuals (P < 0.001). CONCLUSION: In patients with stable ischaemic heart disease, higher GDF11/8 levels are associated with lower risk of cardiovascular events and death. Our findings suggest that GDF11/8 has similar cardioprotective properties in humans to those demonstrated in mice. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Marc A Egerman; Samuel M Cadena; Jason A Gilbert; Angelika Meyer; Hallie N Nelson; Susanne E Swalley; Carolyn Mallozzi; Carsten Jacobi; Lori L Jennings; Ieuan Clay; Gaëlle Laurent; Shenglin Ma; Sophie Brachat; Estelle Lach-Trifilieff; Tea Shavlakadze; Anne-Ulrike Trendelenburg; Andrew S Brack; David J Glass Journal: Cell Metab Date: 2015-05-19 Impact factor: 27.287
Authors: Manisha Sinha; Young C Jang; Juhyun Oh; Danika Khong; Elizabeth Y Wu; Rohan Manohar; Christine Miller; Samuel G Regalado; Francesco S Loffredo; James R Pancoast; Michael F Hirshman; Jessica Lebowitz; Jennifer L Shadrach; Massimiliano Cerletti; Mi-Jeong Kim; Thomas Serwold; Laurie J Goodyear; Bernard Rosner; Richard T Lee; Amy J Wagers Journal: Science Date: 2014-05-05 Impact factor: 47.728
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Bernice Ruo; John S Rumsfeld; Mark A Hlatky; Haiying Liu; Warren S Browner; Mary A Whooley Journal: JAMA Date: 2003-07-09 Impact factor: 56.272
Authors: Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee Journal: Cell Date: 2013-05-09 Impact factor: 41.582
Authors: Tommaso Poggioli; Ana Vujic; Peiguo Yang; Claudio Macias-Trevino; Aysu Uygur; Francesco S Loffredo; James R Pancoast; Miook Cho; Jill Goldstein; Rachel M Tandias; Emilia Gonzalez; Ryan G Walker; Thomas B Thompson; Amy J Wagers; Yick W Fong; Richard T Lee Journal: Circ Res Date: 2015-10-21 Impact factor: 17.367
Authors: Shavonn C Harper; Jaslyn Johnson; Giulia Borghetti; Huaqing Zhao; Tao Wang; Markus Wallner; Hajime Kubo; Eric A Feldsott; Yijun Yang; Yunichel Joo; Xinji Gou; Abdel Karim Sabri; Priyanka Gupta; Maria Myzithras; Ashraf Khalil; Michael Franti; Steven R Houser Journal: Circ Res Date: 2018-11-09 Impact factor: 17.367
Authors: Jessica Garbern; Amy C Kristl; Vinicius Bassaneze; Ana Vujic; Henk Schoemaker; Rebecca Sereda; Liming Peng; Elisabeth M Ricci-Blair; Jill M Goldstein; Ryan G Walker; Shalender Bhasin; Amy J Wagers; Richard T Lee Journal: Am J Physiol Heart Circ Physiol Date: 2019-05-24 Impact factor: 4.733